{"id":"W4415654614","doi":"10.1177/13524585251389797","title":"Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Pharmaceuticals; EMD Serono; MedDay Pharmaceuticals; Siemens Healthineers; Schweizerische Multiple Sklerose Gesellschaft; Eisai; Bundesministerium für Bildung und Forschung; Atara Biotherapeutics; National Institutes of Health; Mylan; TG Therapeutics; Novartis Pharmaceuticals Corporation; Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; Grifols; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Bayer HealthCare; Novartis Pharma; European Commission; Eli Lilly and Company; U.S. Department of Defense; Multiple Sclerosis International Federation; Gemeinnützige Hertie-Stiftung; Sanofi; Neuraxpharm; Teva Pharmaceutical Industries; Novartis; Celgene; Biogen; Deutsche Forschungsgemeinschaft; Genentech; National Multiple Sclerosis Society; GlaxoSmithKline; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Multiple sclerosis; Disease; Central nervous system disease; Degenerative disease; Amyotrophic lateral sclerosis; Clinical neurology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003876694,0.0003246589,0.0009533886,0.0006346998,0.0002601644,0.00007514197,0.0003369814,0.0001365097,0.000007765252],"category_scores_gemma":[0.02987129,0.0002284565,0.0003341098,0.001186053,0.0002989334,0.0003191964,0.0001869491,0.0007984049,7.847455e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003534143,"about_ca_system_score_gemma":0.0005133106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003034887,"about_ca_topic_score_gemma":0.0005322098,"domain_scores_codex":[0.9959948,0.0005690876,0.001434523,0.0005450954,0.0008642586,0.0005922363],"domain_scores_gemma":[0.9841785,0.0135562,0.000740773,0.0005796748,0.0007008132,0.000243975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006766598,0.002845414,0.6824396,0.0003328638,0.0001671478,0.000001828826,0.0004729985,0.001321265,0.2826707,0.000007332661,0.00008185038,0.02289236],"study_design_scores_gemma":[0.01329655,0.0004233841,0.8585848,0.003301102,0.0002128305,0.00000180602,0.0003588825,0.06365911,0.05996774,0.000007145396,0.00002712666,0.0001595242],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658445,0.0004554818,0.02484474,0.005052373,0.0002767914,0.003403833,0.00008321299,0.00002136101,0.00001774178],"genre_scores_gemma":[0.9921554,0.001768052,0.005189185,0.00008863348,0.000118061,0.0005995182,0.00002293278,0.00004104966,0.00001714799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.222703,"threshold_uncertainty_score":0.9783005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1114129641189541,"score_gpt":0.3431834111194926,"score_spread":0.2317704470005386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}